The Mammalian Cell Resource (MCR) Core Is designed to serve the Projects comprising the Program in three major areas: (1) To characterize selected mammalian cell lines, as designated by the Project Leaders, with respect to growth characteristics, chemical and radiation sensitivities (clonogenic survival), and verification of drug-resistance phenotypes conferred by genetic markers (e.g., NEC);the MCR will then act as a repository of cryopreserved, characterized mammalian cell lines, free of mycoplasma, for all Projects, ensuring quality control throughout the Program and providing confidence for inter-Project comparsions. (2) To prepare mammalian cell extracts from specific mammalian cell lines as requested by the individual Projects. (3) To provide advice and assistance for the construction of specialized cell lines (i.e., gene knockdown and knock-out) as requested by individual Projects. Thus there are three Specific Aims of the MCR: (1) To characterize, maintain, and distribute as requested mammalian cell lines which are used by the Projects constituting the Program, for the purposes of ensuring quality control and assuring the validity of inter-Project experimental comparisons; (2) To prepare small (up to 2-liter) custom extracts for mammalian cell lines as requested by the Projects, or large (up to 50-liter) extracts from commercially purchased cells provided by individual Projects; (3) To provide advice and technical assistance as appropriate for the construction and characterization of specialized mammalian cell lines such as shRNA knock-down cell lines, gene disruption (knock-out) cell lines, and cell lines with genetic modifications (e.g., minigene-complemented cell lines, APRT- and HPRT-deficient variants, etc.).
This (Research Project/Core) is part of a multicomponent Program Project with the theme of understanding the processing of complex DNA damage by mammalian cells. The significance to human health is to generate new knowledge and paradigms for modeling DNA repair of DNA interstrand crosslinks (ICLs), to improve therapy using ICL-inducing compounds, and to identify new therapeutic targets for cancer treatment.
|Bacolla, Albino; Cooper, David N; Vasquez, Karen M (2014) Mechanisms of base substitution mutagenesis in cancer genomes. Genes (Basel) 5:108-46|
|Smith, Stephanie; Fox, Jennifer; Mejia, Marco et al. (2014) Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity. PLoS One 9:e87203|
|Wood, Richard D; Lange, Sabine S (2014) Breakthrough for a DNA break-preventer. Proc Natl Acad Sci U S A 111:2864-5|
|Huang, Yaling; Leung, Justin W C; Lowery, Megan et al. (2014) Modularized functions of the Fanconi anemia core complex. Cell Rep 7:1849-57|
|Yousefzadeh, Matthew J; Wood, Richard D (2013) DNA polymerase POLQ and cellular defense against DNA damage. DNA Repair (Amst) 12:1-9|
|Wang, Yucai; Han, Xiao; Wu, Fangming et al. (2013) Structure analysis of FAAP24 reveals single-stranded DNA-binding activity and domain functions in DNA damage response. Cell Res 23:1215-28|
|Bacolla, Albino; Temiz, Nuri A; Yi, Ming et al. (2013) Guanine holes are prominent targets for mutation in cancer and inherited disease. PLoS Genet 9:e1003816|
|Huang, Yaling; Li, Lei (2013) DNA crosslinking damage and cancer - a tale of friend and foe. Transl Cancer Res 2:144-154|
|Wang, Yucai; Leung, Justin W; Jiang, Yingjun et al. (2013) FANCM and FAAP24 maintain genome stability via cooperative as well as unique functions. Mol Cell 49:997-1009|
|Leung, Justin Wai Chung; Wang, Yucai; Fong, Ka Wing et al. (2012) Fanconi anemia (FA) binding protein FAAP20 stabilizes FA complementation group A (FANCA) and participates in interstrand cross-link repair. Proc Natl Acad Sci U S A 109:4491-6|
Showing the most recent 10 out of 52 publications